French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

PARIS: France’s Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost ...

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker's biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer-healthcare arm ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical ...